Phylogeny of partial \( gag \), \( pol \) and \( env \) genes show predominance of HIV-1G and CRF02_AG with emerging recombinants in south-eastern Nigeria

Augustine O. Udeze\(^a,b\), David O. Olaleyeb, Georgina N. Odaibo\(^a,\ast\)

\(^a\) Department of Virology, College of Medicine, University College Hospital, Ibadan, Nigeria
\(^b\) Virology Unit, Department of Microbiology, University of Ilorin, P.M.B 1515, Ilorin, Nigeria

**Keywords:**
Bioinformatics
Genetics
Microbiology
Virology
Epidemiology
Infectious disease
Genetic sequences
Circulating
HIV-1
Subtypes
Phylogeny
South-eastern Nigeria

**ABSTRACT**

Human Immunodeficiency Virus is characterized by high degree of genetic diversity with marked differences in its geographic distribution even within a country. This study was designed to identify the strains of HIV-1 circulating among infected individuals in southeastern parts of Nigeria.

Genomic DNA was extracted from blood samples of 30 HIV-1 infected individuals from Anambra, Delta and Imo states of southeastern Nigeria. Portions of the genome corresponding to entire p24 gag, entire protease and C2–V3 env genes were amplified by nested PCR, sequenced using Sanger’s method and phylogenetically analysed. Out of the 30 samples sequenced, 17, 28 and 14 readable sequences were obtained for gag, pol and env regions respectively. The most prevalent subtypes were CRF02 AG (41.2% in gag, 57.1% in pol protease and 50.0% in env) and G (29.4% in gag, 35.7% in pol protease and 35.7% in env). Other subtypes identified include A (17.7% in gag, 7.1% in env) and J (7.1% in env). Also 2 sequences each in gag (11.8%) and pol protease (7.1%) regions were unclassified but preliminary analysis showed they are recombinants. Furthermore, 71.4% of the isolates with sequences in the 3 regions and 26.7% of those with sequences in 2 genomic regions were recombinant forms. CRF02 AG and subtype G are the predominant HIV-1 strains circulating among infected individuals in southeastern Nigeria. Preliminary analysis results of unclassified sequences suggest that they are new recombinants.

1. Introduction

Human Immunodeficiency Virus type 1 (HIV-1) is genetically highly diverse as a result of its high rate of replication \([1, 2]\), mutation \([3]\) and recombination \([4, 5, 6]\). Presently, there are four groups of HIV-1 including M (major), O (outlier), N (new) and P (putative). Group M is responsible for ‘90% of cases of HIV infection globally \([7]\) and has evolved into multiple genetic forms termed subtypes, subsubtypes, circulating recombinant forms (CRFs) and unique recombinant forms (URFs). Nine subtypes which include A-D, F-H, J and K have been identified till date. CRFs arise as a result of recombination events occurring between two or more subtypes. Presently, more than 79 CRFs have been identified and more are still being identified. In addition, URFs are being reported in individuals infected with two or more HIV-1 clades in areas where multiple variants are circulating \([8]\).

The distribution of the different variants varies by regions globally. While clade B is predominant in Europe and the Americas, the epidemic in Southern and Eastern Africa, India and Nepal is predominated by clade C \([9, 10]\). In West and West Central Africa, most viruses are CRF02-AG \([11, 12, 13]\) while subtype D is generally limited to East and Central Africa, with sporadic cases observed in Southern and Western Africa \([14, 15, 16]\). Pure clade E has never been isolated but rather appears as an A/E mosaic which has been detected in Thailand, the Philippines, China and Central Africa \([14, 15]\). Subtype F has been reported in Central Africa \([17, 18]\), South America \([19]\) and Eastern Europe \([20, 21]\) while G and A/G recombinants have been observed in Western and Eastern Africa as well as in central Europe \([15]\). Subtypes H and J were described in Central Africa \([22, 23, 24]\) and in Angola \([25, 26]\). Clade K has been identified in the Democratic Republic of Congo and Cameroon \([27]\).

In Nigeria, the complex nature of the circulating strains has been demonstrated \([28]\) with multiple subtypes and CRFs of HIV-1 and HIV-2 already reported \([29, 30, 31, 32, 33, 34]\). Most of these have been based on isolates from the south-western and northern regions of the country. With attention gradually shifting to development of candidate vaccine, its success in Nigeria will largely depend on adequate knowledge of all the circulating strains of the virus from the different regions of the
country. In this study we determined the HIV-1 strains circulating in south-eastern Nigeria.

2. Materials and methods

2.1. Study population

The study population consisted of 30 consenting HIV-1 infected individuals assessing HIV clinics at General Hospital Awo-Omamma, Imo state, State Hospital Asaba, Delta state and St Joseph’s Catholic Hospital Adazi Anambra state between February and May 2012. They included 11 males and 19 females with mean age of 39.6 years (range: 3–70 years). Ethical approval UI/EC/11/0178 was obtained for this study from University of Ibadan/UCH ethical review board and the study conformed to Ethics of Human subjects use in research following the Helsinki Declaration. Informed consent was obtained from adult participants, while parental assent was obtained from young persons under 18 years of age.

2.2. Sample collection, preparation and storage

Blood sample was collected from each patient by venepuncture into Ethylene Diamine Tetra Acetic Acid (EDTA) bottle and properly labelled with date of collection and laboratory identification number. Plasma was separated from each sample by centrifugation at 3000 rpm for 5 min and aspirated into sterile cryovials. Both the plasma and packed cells were stored at -20 °C until analysed.

2.3. DNA extraction and precipitation

Genomic DNA was extracted from the packed blood cells using modified phenol-chloroform extraction procedure followed by ethanol precipitation [35]. Five hundred microliters (500μl) of packed blood cells was dispensed into Eppendorf tube and equal volume of equilibrated phenol/chloroform (50:50) was added. The tube was vortexed vigorously and spun in a centrifuge at top speed (16,000 rpm/25,000 rf) for 3 min to separate the phases. The aqueous phase was aspirated into a new Eppendorf tube and equal volume of chloroform added. The tube was then vortexed vigorously and spun as above to remove any traces of phenol. The aqueous phase was aspirated into a new Eppendorf tube carefully. This step of addition of chloroform to remove traces of phenol was repeated until no visible protein interface between the chloroform and the aqueous phase was seen. The aqueous phase was aspirated into a new Eppendorf tube carefully. Fifty microliters (50μl) of 3M sodium acetate and 1 ml of 100% ethanol was added into the tube. The tube was vortexed and frozen at -80 °C for 40 min. The tube was spun at full speed in a centrifuge for 30 min at 4 °C and the supernatant decanted. Three hundred microliters (300μl) of 70% ethanol was added to the DNA pellet, vortexed and spun for 5 min at 4 °C. The supernatant was decanted and the pellet was air dried at 37 °C for approximately 10 min. The DNA was re-suspended by adding 50μl of 1XTE buffer. The tube was then vortexed and centrifuged for 10 s to pool the sample and then stored at -20 °C until used. The extraction was done inside level 3 biosafety cabinet.

2.4. PCR amplification

Nested PCR was used for the amplification of regions of HIV-1 gag, pol and env genes corresponding to entire p24 gag region, the entire 297 bp of protease (PR) region and C2–V3 env domain. Details of the primers used are shown in Table 1. The thermal-time profile for the amplification of p24 gag, pol protease and env C2–V3 regions are as previously described by Ajoge et al. [32], Ojesina et al. [36] and Kanki et al. [37] respectively. The reactions were performed in a thermal cycler (Applied Biosystems GeneAmp PCR System 9700™). PCR reactions were carried out in a 50μl volume reaction mixture containing 10 μl of DNA and 10 μl of ampiclon for first and second round reactions respectively, 10 μl (1X) of PCR mix (Jena Bioscience, Germany), 2 μl (0.4μmol) each of the primers and 26 μl of nuclease-free water. Electrophoresis of the amplicons was run using 1.5% agarose gels stained by ethidium bromide at 120 V and a current of 500 mA for 60 min. The bands were visualized using Bio Rad gel documentation system.

2.5. Sequencing

Only samples with positive PCR products were sequenced for this study. PCR products were purified using WIZARD Purification Kit Protocol (Promega) and subjected to direct sequencing of both sense and antisense strands using Big Dye Terminator Cycle Sequencing Ready Reaction kit v3.1 (Applied Biosystems, Foster City, CA, USA) with the second round primers and then analysed in the Genetic Analyzer 3130xl (Applied Biosystems, California, USA). All nucleotide sequences obtained in this study have been deposited at the GenBank and assigned the accession numbers MF458121-MF458137 for gag sequences, MF458138-MF458165 for protease sequences and MF581058-MF581071 for env sequences.

2.6. Phylogenetic analysis

Sequences were manually edited using combination of CLC BIO (QIAGEN®, USA), MEGA 6.06 [38] and sequence scanner v1.0 (Applied Biosystems, USA) software. The sequences were aligned by ClustalW with reference sequences from HIV Sequence Database at Los Alamos (www.hiv.lanl.gov). Phylogenetic inferences were performed by the neighbour-joining method with 1,000 bootstrap replicates under Kimura's two-parameter correction using MEGA 6.06. The evolutionary distances were computed using the Maximum Composite Likelihood

| Region | Name of primer | Primer Sequence (5’ -3’) | HXB2 Position | PCR | Orientation | Size of Product (bp) | Reference |
|--------|----------------|--------------------------|---------------|-----|-------------|----------------------|-----------|
| P24 gag| G00            | GACTAGGGAGGCTAGAAG        | 764-782       | 1st | Forward     | 1518                 | [32]      |
| G01    | AGGGGTGGTTGGCAAAAGA | 2264-2281              | 1st           | Forward | 717      |
| G60del3G | CAGCCTAAAATCCCTATAGTGA | 1173-1197              | 2nd           | Reverse | 2959     |
| G25    | ATGCTCTCAGCAAAAAACTTGG | 1867-1889              | 2nd           | Reverse | 2959     |
| Protease | OJ1       | AAATGATGAGAGGATGTGGAGAG | 1823-1846     | 1st | Forward     | 2375                 | [36]      |
| OJ2    | TATCTAAGTGGCTTTGCTCAAT | 4173-4197              | 1st           | Reverse | 2375     |
| OJ3    | AGACAGGCTATTTTTAGGGGA | 2074-2095              | 2nd           | Reverse | 2375     |
| OJ4    | CATCTCTTCTTCTTCTTCTTGG | 2574-2597              | 2nd           | Reverse | 2375     |
| Env C2–V3 | WT1       | GCTTGGTTGGGATCATAAGTGA | 6884-6908     | 1st | Forward     | 494                  | [37]      |
| WT2    | CAATGAGAAAAATCCTCTCCAAT | 7353-7377              | 1st           | Reverse | 494      |
| KK40   | ACACTGAAATTGGGAGCATGGA | 6954-6973              | 2nd           | Reverse | 384      |
| KK30   | AATTCTTGGGCTTTGCTTGG | 7318-7337              | 2nd           | Reverse | 384      |
method and are in the units of the number of base substitutions per site [39].

3. Results

3.1. HIV-1 subtypes

Out of the 30 samples analysed, 17 gag, 28 pol and 14 env sequences were obtained. Phylogenetic analysis showed that out of the 17 gag sequences, 3 (17.7%), 5 (29.4%) and 7 (41.2%) were HIV-1A, HIV-1G and CRF02_AG respectively while 2 (11.8%) did not cluster with any of the known subtypes or CRFs. Blast results of these two sequences, NG_AN.12_04 and NG_AN.12_07 from the Los Alamos HIV-1 sequence database showed that the isolates had closest similarity to HIV-1 CRF02_AG and are hereby referred to as unclassified 02AG (U02AG). For the pol sequences, 10 (35.7%) and 16 (57.1%) were HIV-1G and CRF02_AG respectively while 2 (7.1%) sequences did not cluster with any of the known subtypes or CRFs. Blast results of these two sequences, NG_DE.12_09 and NG_IM.12_06 from the Los Alamos HIV-1 sequence database also showed that the isolates had closest similarity to HIV-1 subtype G and are hereby referred to as unclassified subtype G (U06). Analysis of env sequences showed that 5 (35.7%) were HIV-1G, 7 (50.0%) CRF02_AG, 1 (7.1%) HIV-1A and 1 (7.1%) HIV-1L. Neighbour joining (NJ) tree analysis of gag, pol and env sequences are shown in Figures 1, 2, and 3 respectively.

3.2. Genetic diversity

Seven (23.3%) of the 30 isolates were sequenced in the 3 fragments of gag, pol and env genes, 15 (50.0%) were sequenced in two of the three fragments while only one fragment was sequenced in 8 (26.7%) (Table 2). Further analysis showed that only 2 (28.6%) of the 7 isolates that were sequenced in the 3 fragments had subtype concordance in all the regions while 5 (71.4%) showed discordant subtypes/forms. Out of the 15 isolates that were sequenced in two fragments, 11 (73.3%) were subtype concordant in both regions while 4 (26.7%) showed discordant subtypes/forms (Figure 4).

4. Discussion

This study shows the circulation of HIV-1 subtypes A, G, CRF02_AG, and J in different proportions among HIV-1 infected individuals in Southeastern Nigeria. The predominance of CRF02_AG; 41.2% in gag region, 57.1% in pol protease region and 50% in env C2-V3 region and subtype G; 29.4% in gag region, 35.7% in pol protease region and 35.7% in env C2-V3 region in this study is consistent with previous reports on isolates from other parts of the country. In their separate studies, Odaibo et al. [40], Ojesina et al. [36], Sankale et al. [28], Fayemivo et al. [33] and Donbraye et al. [34] reported predominance of CRF02_AG and subtype G in circulation in Ibadan, Oyo state, south-western Nigeria. Similarly, molecular studies conducted in Jos, north central Nigeria at different times also reported the predominance of subtypes G and CRF02_AG [32, 41]. Also in a more widespread study covering Lagos and Ibadan (South West), Jos (North Central) and Maiduguri (North East) Nigeria by Chaplin et al. [42] which evaluated RT and PR genes of 338 samples, 45.0% of CRF02_AG, 37.9% of subtype G, 4.4% of CRF06_cpx and 3.6% of subtype A were reported while others accounted for the remaining 9.2%. These studies all show the predominance of HIV-1 CRF02_AG in Nigeria which is believed to be largely driving the epidemic in the country. Our study also shows the circulation of HIV-1 subtype A at 17.7% and 7.1% based on the regions of HIV-1 gag and env C2-V3 genes respectively. Although this subtype accounted for relatively small proportion in this study, it has earlier been reported by Peeters and Sharp [13] as the major circulating subtype accounting for 61.3% in a study that included isolates from four states of the country. Similarly, a national molecular epidemiologic survey of HIV-1 strains that included samples from 34 of the 36 states of Nigeria reported a high percentage (44.8%) of HIV-1 subtype A based on env gp41 gene [43]. It is interesting to know from these reports that the studies conducted in early year 2000 showed higher proportion of HIV-1 subtype A in circulation in different regions of Nigeria. More recent studies including ours however, are increasingly showing predominance of CRF02_AG and subtype G in different regions of the country. Previous researchers have reported that the distribution of HIV-1 genetic diversity with respect to geographic location is highly dynamic with novel genetic diversity continually being generated through mutation and recombination with travel and migration promoting the transfer of diverse viral strains within and between populations over time [44]. The prototype CRF02_AG (IbNg) was initially characterised as subtype A based on partial genome sequencing [45, 46].

Another significant finding from this study is the identification of HIV-1 env C2–V3 subtype J isolate. As far as it can be ascertained, this is the second report of this subtype in Nigeria after it was first reported in 2002 by Agwale and colleagues [43]. Detection of HIV-1 subtype J in the south east may be an indication that the virus strain is spreading to other parts of the country. HIV-1 subtype J has been reported in Democratic Republic of Congo, Angola, Botswana, Cameroon, Central African Republic, Gabon, Senegal, Uganda and Zambie and some European countries like Sweden, Belgium, Spain, France, Portugal, Germany and Italy as well as United States of America and Cuba (Los Alamos HIV Database). However, the isolate in this study closely clustered with sequence from Cameroon which shares common border with Nigeria suggesting that the strain may have been introduced into the country by trans-border travels between these two countries. Travelers contribute to the spread of HIV-1 genetic diversity worldwide, and in the developing world migration of rural populations and civil war are additional contributing factors [47, 48]. Interestingly, this isolate, NG.IM.12.09 grouped with subtype J in the env region same as the one earlier reported by Agwale and colleagues. In the gag region however, it grouped with CRF02_AG while sequence was not available for classification in the pol region. This recombinant virus may represent a new recombinant form whose true mosaic structure can only be ascertained by full-length genome sequence analysis.

Also of importance in this study is the identification of two isolates, NG_AN.12.04 and NG_AN.12.07 (U02AG’s), which did not cluster with any known subtype or CRF in the gag p24 phylogenetic tree. NG_AN.12.04 was classified as CRF02_AG in both pol protease and env C2–V3 regions. NG_AN.12.07 was also classified as CRF02_AG in the pol protease region while sequence was not available for classification in the env C2–V3 region. Similarly two isolates, NG.DE.12.09 and NG.IM.12.06 (U05) also failed to cluster with any known subtype or CRF in the pol protease phylogenetic tree. In the gag and env C2–V3 trees, isolate NG.IM.12.06 grouped with subtype G while there was no available sequences for NG.DE.12.09 for classification in the gag and env regions. Inability of these sequences to cluster with any of the subtypes could be as a result of one or more of the following: (1) insufficient phylogenetic information within the gene fragment, (2) presence of recombinant breakpoint within the sequence that could not be detected in the gene fragment or (3) the gene regions belonged to some previously unidentified virus. Indeed, these sequences may represent new and emerging CRFs or unique recombinant forms (URFs) in the study location. This further reflects the complexity of genetic diversity of HIV-1 strains circulating in Nigeria as earlier reported [28].

Another striking observation in this study is the level of discordant subtypes recorded among the isolates in which more than one genomic region were genotyped. Of the 7 samples sequenced in the three regions of gag, pol and env genes, 5 (42.9%) had discordant subtypes in these genomic regions. In the 15 samples where two genomic regions were sequenced, 3 (20%) had discordant subtypes while the rest had concordant subtypes. The frequent non-concordance among the PCR results for the gag, pol and env genes might be due to marked genetic heterogeneity of the virus in these gene regions. This also demonstrates the complex diversity of the strains of HIV-1 circulating in south-eastern part of Nigeria and hence the need to sequence the complete genome of these
Figure 1. Phylogenetic tree of study gag sequences and reference sequences from Los Alamos database (www.hiv.lanl.gov). Only bootstrap values (1000 replicates) ≥ 70% are shown. The study sequences are indicated by “●” symbol. It indicates isolates from eastern Nigeria.
isolates: recombinant strains have been observed mostly in areas where multiple subtypes co-circulate [49]. Mosaic viruses may have biological advantages over the parental strains as the "hybrid virus" which emerged as a result of recombination events between two or more variants could acquire some advantageous traits from the parental strains. This could manifest in the modification of cell tropism, enhanced co-receptor usage, changes in growth kinetics, and improved viral fitness. The clinical implication of this changing landscape of HIV strains in the region can be quite enormous. The sensitivity of diagnostic kits can be affected as well as reduction in the susceptibility of the isolates to the existing

Figure 2. Phylogenetic tree of study pol sequences and reference sequences from Los Alamos database (www.hiv.lanl.gov). Only bootstrap values (1000 replicates) ≥ 70% are shown. The study sequences are indicated by "●" symbol. It indicates isolates from eastern Nigeria.
Figure 3. Phylogenetic tree of study V3 loop sequences and reference sequences from Los Alamos database (www.hiv.lanl.gov). Only bootstrap values (1000 replicates) > 70% are shown. The study sequences are indicated by “●” symbol. It indicates isolates from eastern Nigeria.
antiretroviral drugs (ARDs) [50, 51]. This might result in the failure of existing diagnostic kits to detect certain strains of the circulating virus as well as poor prognosis of patients on the existing ARDs. This ugly scenario therefore is a cause for concern and calls for constant monitoring for the likely emergence of new/novel inter-subtype recombinant or even secondary recombinant strains as the epidemic progresses. The limitation of this study however is the small sample size analysed. The 30 samples analysed are samples in which the three genomic regions were successfully amplified out of which readable sequences were obtained for 17, 28 and 14 in the gag, pol and env genomic regions respectively. A larger sample size would have shown a more accurate picture of the situation. In conclusion, the predominant HIV-1 subtypes circulating in Eastern parts of Nigeria are CRF02_AG and G. Identification of mosaic strains including unclassifiable sequences highlights the complexity of HIV epidemic in the region. The unclassifiable sequences in this study may represent new/emerging strains whose true identity can only be ascertained by more elaborate study with larger sample size and full-length genome sequence analysis. The extensive variability of HIV-1 strains in the region will undoubtedly impact negatively on the development of candidate vaccine.

**Declarations**

**Author contribution statement**

Augustine O. Udeze: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed

**Table 2. Frequency of occurrence of HIV-1 subtypes and forms among the patients.**

| GAG/POL/ENV Subtype/CRF | Number of samples (%) | Total (%) |
|-------------------------|-----------------------|-----------|
| A/G/A                   | 1 (3.3)               |           |
| U02AG/CRF02_AG/CRF02_AG | 1 (3.3)               |           |
| G/G/G                   | 1 (3.3)               |           |
| G/CRF02_AG/CRF02_AG     | 1 (3.3)               |           |
| CRF02_AG/CRF02_AG/G     | 1 (3.3)               |           |
| G/U02AG                 | 1 (3.3)               |           |
| G/G/#                   | 2 (6.7)               | 15 (50.0) |
| #/G/G                   | 2 (6.7)               |           |
| U02AG/CRF02_AG/#        | 1 (3.3)               |           |
| #/CRF02_AG/CRF02_AG     | 1 (3.3)               |           |
| A/G/#                   | 1 (3.3)               |           |
| CRF02_AG/CRF02_AG/#     | 1 (3.3)               |           |
| A/CRF02_AG/#            | 1 (3.3)               |           |
| CRF02_AG/#/J            | 1 (3.3)               |           |
| #/#/J                   | 1 (3.3)               |           |
| #/U02AG                 | 1 (3.3)               |           |
| #/CRF02_AG/#            | 2 (6.7)               | 15 (50.0) |
| CRF02_AG/#/#            | 1 (3.3)               |           |
| Key: # = Sequence not available, U02AG = unclassified CRF02_AG, UG = unclassified subtype G. |

**Figure 4.** Percentage concordant and discordant Subtypes/CRFs among the HIV-1 infected patients.
reagents, materials, analysis tools or data; Wrote the paperdraft of the manuscript and approved the final version.

David O. Uholeye, Georgina N. Odaibo: Conceived and designed the experiments; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Funding statement

This work was partially supported by the HIV/Hepatitis project of the Department of Virology, COM, UI.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

Acknowledgements

The authors would like to thank all the study participants and the management of the different hospitals for granting access to the patients.

References

[1] X. Wei, S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, P. Deutsch, J.D. Lifson, S. Bonhoeffer, M.A. Nowak, B.H. Hahn, M.S. Saag, G.M. Shaw, Viral dynamics in human-immunodeficiency-virus type 1 infection, Nature 373 (1995) 117–122.

[2] A.S. Perelson, A.U. Neumann, M. Markowitz, J.M. Leonard, D.D. Ho, HIV-1 dynamics in vivo: viral clearance rate, infected cell lifespan, and viral generation time, Science 271 (1996) 1582–1586.

[3] F. Gao, Y. Chen, D.N. Levy, J.A. Conaway, T.B. Kepler, H. Hui, Unselected mutations in the human immunodeficiency virus type 1 genome are mostly non synonymous and often deleterious, J. Virol. 78 (2004) 2425–2433.

[4] T. Rhodes, H. Wargo, W.-S. Hu, High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication, J. Virol. 77 (2003) 11193–11200.

[5] D.N. Levy, J.A. Conaway, T.B. Kepler, H. Hui, Unselected mutations in the human immunodeficiency virus type 1 genome are mostly non synonymous and often deleterious, J. Virol. 78 (2004) 2425–2433.

[6] M.E. Quinones-Mateu, E.J. Arts, Recombination in HIV-1: update and implications, AIDS Rev. 1 (1999) 89–109.

[7] F. Simon, P. Mauclere, P. Roques, I. Loussert-Ajaka, M.C. Muller-Trutwin, I. Bartolo, C. Rocha, J. Bartolomeu, A. Gama, E. Mpuudi-Ngige, N. Nzelambi, High diversity of HIV-1 subtype F strains in central Africa, Virology 259 (1999) 99–109.

[8] J.J. Sankale, S. Langvine, G.O. Gaidh, D.M. Meloni, A.L. Ojeina, D. Obalaye, P. Kanki, The complexity of circulating HIV type 1 strains in Oyo state Nigeria, AIDS Res. Hum. Retrovir. 23 (8) (2007) 1025–1028.

[9] O.D. Olaleye, L. Bernstein, C.C. Ekweozor, Z. Sheng, S.A. Omiulu, X.Y. Li, J. Janson-Halley, S. Rasheed, Prevalence of human immunodeficiency virus types 1 and 2 in infections in Nigeria, J. Infect. Dis. 167 (3) (1993) 710–714.

[10] O.D. Olaleye, C.C. Ekweozor, Z. Sheng, S. Rasheed, Evidence of serological cross-reactivities with human immunodeficiency virus types 1 and 2 and human T- lymphotropic virus types I and II in sera of pregnant women in Ibadan, Nigeria, Int. J. Epidemiol. 24 (1) (1995) 198–203.

[11] G.N. Odaibo, O.D. Olaleye, H. Burghac, O.G. Okafor, U. Dietrich, Multiple presence and heterogeneous distribution of HIV-1 subtypes in Nigeria, Biosci. Res. Commun. 13 (4) (2001) 447–458.

[12] H.O. Ayode, M.L. Gordon, T. de Oliveira, T.N. Green, S. Ibrahim, O.S. Shittu, S.O. Ooniola, A.A. Ahadu, T. Ndugo, Genetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02_AG isolates, PLoS One 6 (3) (2011), e17385.

[13] S.A. Fayemiwo, O.N. Odaibo, J.L. Sankale, A.A. Oni, R.A. Bakare, O.D. Olaleye, P. Kanki, Diverse Genetic Subtypes of HIV-1 among female sex workers in Ibadan, Nigeria, Afr. J. Clin. Exp. Microbiol. 15 (1) (2014) 1–8.

[14] E. Donbraye, G.N. Odaibo, D.O. Olaleye, Coreceptor usage of Human Immunodeficiency virus type 1 strains in Ibadan, Nigeria, Int. STD Res. Rev. 3 (2015) 52–62.

[15] M. Peruczo, M. Goldfarb, K. Shimizu, C. Lama, J. Fogh, M. Wigler, Human-tumor derived cell lines contain common and different transforming genes, Cell 27 (1981) 461–476.

[16] A.I. Ojeina, J. Sankale, G. Odaibo, S. Langleiv, S.T. Meloni, A.D. Sankale, P. Obalaye, J.P. Kanki, Subtype-specific patterns in HIV type 1 reverse transcriptase and protease in Oyo state, Nigeria: implications for drug resistance and host response, AIDS Res. Hum. Retrovir. 22 (8) (2006) 770–779.

[17] P. Kanki, D.J. Hamel, J.J. Sankale, C. Hieh, I. Thoir, F. Barin, S.A. Woodcock, A. Gueye-Ndiaye, E. Zhang, M. Montano, T. Siby, R. Marlink, I. Dreyer, M.E. Esset, S. Mboup, Human immunodeficiency virus type 1 subtypes differ in disease progression, J. Infect. Dis. 179 (1999) 68–73.

[18] K. Tamura, G. Stecher, D. Peterson, A. Filipski, S. Kumar, Molecular evolutionary genetics analysis version 6.0, Mol. Biol. Evol. 30 (12) (2013) 2725–2729.

[19] K. Tamura, D. Peterson, N. Peterson, G. Stecher, M. Nei, S. Kumar, Molecular evolutionary genetics analysis using Maximum likelihood, evolutionary distance, and Maximum parsimony methods, Mol. Biol. Evol. 28 (11) (2011) 7317–7319.

[20] G.N. Odaibo, D.O. Olaleye, L. Heyndrickx, K. Verrecken, K. Houver, W. Janssen, Mother-to-child transmission of different HIV-1 subtypes among ARV Naive infected pregnant women in Nigeria, Rev. Int. Med. Trop. Sao Paulo 48 (2006) 77–80.

[21] P. Lar, N. Lar, K. Bemis, J. Jelpe, L. Enzynguere, L. Ayuba, D. Zella, P. Kanki, J.K. Carr, W. Blatner, A.G. Abimiku, HIV subtype and drug resistance patterns among drug naive persons in Jos, Nigeria, Afr. J. Biotechnol. 6 (16) (2007) 1892–1897.

[22] B. Chaplin, G. Eisen, J. Idoko, D. Omuwereku, E. Idjide, I. Adewole, W. Gashau, S. Meloni, A.D. Sall, J.J. Sankale, E. Elong, R.L. Murphy, P. Kanki, Impact of HIV 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy, AIDS Res. Hum. Retrovir. 27 (1) (2011) 71–80.

[23] S.M. Agwale, C. Zeh, K.E. Robbim, L. Odama, A. Saekhou, A. Edubio, M. Njoku, N. Okeke, M.S. Ghone, G.N. Odaibo, C. Mutuz, D. Hone, D. Pieniadzie, C. Wambiso, M.L. Kabilis, Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials, Vaccine 20 (16) (2002) 2131–2139.
[44] R.J. Gifford, T. de Oliveira, A. Ramalho, O.G. Pybus, D. Dunn, A.M. Vandamme, P. Kellam, D. Fillay, Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1, J. Virol. 81 (23) (2007) 13050-13056.

[45] T. Howard, O.D. Olaleye, S. Rasheed, Sequence analysis of gp120 coding region of a new subtype A strain of HIV-1 (HIV-1 IbNg) from Nigeria, AIDS Res. 10 (4) (1994) 1755-1757.

[46] O.D. Olaleye, Z. Sheng, T. Howard, S. Rasheed, Isolation and characterization of a new subtype A variant of human immunodeficiency virus type 1 from Nigeria, Trop. Med. Int. Health 1 (1) (1996) 97-106.

[47] L. Perrin, L. Kaiser, S. Verly, Travel and the spread of HIV-1 genetic variants, Lancet Infect. Dis. 3 (1) (2003) 22-27.

[48] M.M. Thomson, R. Najera, Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update, AIDS Rev. 7 (4) (2005) 210-224.

[49] L. Heyndrickx, W. Janssens, L. Zekeng, R. Muondza, S. Anagonou, G. Van der Auwera, S. Coppens, K. Vereecken, K. De Witte, R. Van RAMPelbergh, M. Kabundo, L. Morison, F.P. McCutchan, J.K. Carr, J. Albert, M. Féné, J. Goudsmidt, B. Asjo, M. Salminen, A. Buvé, G. Van Der Groen, Simplified strategy for detection of recombinant human immunodeficiency virus type 1 Group M Isolates by gag/env heteroduplex mobility assay, J. Virol. 74 (2000) 365-370.

[50] J.C. Planier, M. Djemai, V. Lemee, A. Reggiani, M. Leoz, L. Burc, A. Vessiere, D. Rouset, J.D. Poveda, C. Henquell, A. Gauthier-Dejean, F. Barin, Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections, J. Clin. Microbiol. 47 (9) (2009) 2996-2997.

[51] B. Senechal, V.L. James, Ten years of external quality assessment of human immunodeficiency virus type 1 RNA quantification, J. Clin. Microbiol. 50 (11) (2012) 3614-3619.